Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: fred hayes who wrote (9869)	12/4/2006 5:03:28 PM
From: Iamarangerboy	Read Replies (1) of 10280

Pfizer Seen Using Immediate, Long-Term Fixes For Drug Loss Dec 4, 2006 15:51:00 (ET) Pfizer Inc. (PFE), stung by the loss of a once promising heart-disease treatment, now must take both near-term and long-term steps to improve its financial prospects. ........ The Pfizer setback seemed to renew speculation the company was interested in acquiring Sepracor Inc. (SEPR), which sells the anti-insomnia drug Lunesta. Sepracor was a rumored takeover target earlier this year after Pfizer ended its collaboration with Neurocrine Biosciences Inc. (NBIX) for an experimental sleep drug, which had hit a regulatory setback. Such an acquisition would give Pfizer access to a fast-selling drug that's marketed to general-practice doctors -- a marketing segment in which Pfizer excels. For Pfizer, Sepracor would be "a relatively unencumbered asset that feeds into their whole kind of infrastructure of selling to the general practitioner," said Vincent Aita, partner with Kilkenny Capital Management, which invests in drug stocks but doesn't own Pfizer or Sepracor. Spokespeople for Sepracor and Pfizer couldn't immediately be reached. Sepracor shares rose 4.5% Monday to $57.75.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next